NCT01226056暂停1 期
Phase I/II Trial With Sorafenib in Combination With RAD001 Administered Orally in Patients With Advanced Solid Tumors, Selected on the Base of Molecular Targets
Southern Europe New Drug Organization1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2009年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 暂停
- 发起方
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- Phase I: Maximum Tolerated Dose (MTD)
研究概览
简要总结
Sorafenib is an oral multikinase inhibitor and among its targets are several RTKs involved in tumor genesis (Raf, Flt-3, c-Kit and RET) and angiogenesis (VEGFR1, 2 and 3 and PDGFRß). Therefore sorafenib inhibits tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and Kit signaling) and/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling.
RAD001 is a novel derivative of rapamycin. It selectively inhibits mTOR directly blocking tumor cells by preventing tumor cell growth and proliferation and indirectly by inhibiting angiogenesis (via potent inhibition of the HIF-1 and consequently VEGF production).
Targeting mTOR in combination with sorafenib might lead to more profound effects on tumor cell biology than could be achieved through individual targeting of some proteins.
New drugs have often met only limited success since not always target pathways responsible for tumor development and growth are targeted. To overcome this problem, the specific pathways targeted by the investigators two drugs will be analyzed in each single patient before the inclusion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with progressive disease of advanced solid tumours judged non suitable for standard treatment
- •Biopsiable lesion or archive tissue not older than 1 year to assess the expression of:
- •phosphorylated AKT
- •phosphorylated p70S6
- •RKIP (Raf Kinase Inhibitor Protein)
- •phosphorylated ERK1/2 The presence of at least one of the previous targets will be mandatory for patient enrolment
- •At least 1 uni-dimensional measurable lesion according to modified RECIST
- •Life expectancy of at least 12 weeks
- •Age ≥ 18 years old
- •ECOG Performance Status of 0 or 1
- •Adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of first dose:
- •Haemoglobin ≥9.0 g/dL (5.6 mmol/L)
- •Absolute neutrophil count (ANC)≥1.5 x 109/L
- •Platelet count ≥100 x 109/L
- •Total bilirubin ≤1.5 x upper limit of normal (ULN)
- •ALT and AST ≤2.5 x ULN (≤5 x ULN for patients with liver involvement of their cancer)
- •Alkaline phosphatase ≤4 x ULN
- •PT-INR/PTT <1.5 x ULN
- •Serum albumin levels ≥2.5 mg/dl
- •Serum creatinine ≤1.5 x ULN
- •HBV/HCV testing in the 2 weeks before treatment start in specific categories of patient with hepatitis B and C risk factors and in additional patients at the discretion of the investigators according to guidelines in Appendix
- •All fertile patients must use adequate contraception while on study and for three subsequent months
- •Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained prior to performing any study specific procedures
排除标准
- •History of cardiac disease: congestive heart failure (NYHA II-IV), active coronary artery disease - CAD (MI more than 6 months prior to study entry is allowed), cardiac arrhythmias requiring antiarrhythmic therapy (betablockers or digoxin are permitted) or uncontrolled hypertension
- •History of HIV infection or chronic hepatitis B or C
- •Patients with NSCLC squamous histotype
- •Recurrent hemoptysis or cerebrovascular accident within 12 months, or peripheral vascular disease with claudication on less than 1 block (about 150 metres), or history of clinically significant bleeding non-traumatic
- •Deep venous thrombosis or pulmonary embolus within 1 year or ongoing need for full-dose oral or parenteral anticoagulation
- •Clinically active infections (> Grade 2 NCI-CTC AE version 3.0)
- •Evidence of CNS tumor metastases
- •History of organ allograft
- •Pre-existing thyroid abnormality where thyroid function cannot be maintained in the normal range by medication
- •Serious, non-healing wound, ulcer, or bone fracture
- •Second malignancies within the past 5 years (except for non - melanoma skin cancer and cervical carcinoma in situ)
- •Pregnant or breast-feeding patients
- •Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
- •Any condition that is unstable or could jeopardize the safety of the patient and his/her compliance in the study
- •Patients unable to swallow oral medications
- •Any malabsorption condition
- •Prior treatment with sorafenib or m-TOR inhibitors
- •Ongoing requirement for systemic corticosteroid medication or other immunosuppressants
- •Radiotherapy within 3 weeks of start of study drug. Palliative radiotherapy is allowed. Major surgery within 4 weeks of study entry
- •Radiotherapy involving > 30% of the active bone marrow
- •Autologous bone marrow transplant or stem cell rescue within 4 months of study entry
- •Use of biologic response modifiers, such as G-CSF, within 3 week of study entry. Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study or planned during the study period
- •Investigational drug therapy outside of this trial during or within 4 weeks of study entry
研究组 & 干预措施
RAD001 in combination with sorafenib
Experimental
干预措施: RAD001 in combination with sorafenib (Drug)
结局指标
主要结局
Phase I: Maximum Tolerated Dose (MTD)
时间窗: 6 weeks
The maximum tolerated dose (MTD) is defined as the dose in which 2 of 3 or 2 of 6 patients experience a DLT. The Recommended Dose is identified as one dose level below the MTD.
Phase II: PFS (Progression Free survival) rate
时间窗: 3 months
次要结局
- Phase I: Pharmacokinetics profile of both drugs(6 weeks)
- Phase II: overall survival(15 months)
- Tumor response(every 8 weeks)
- Objective Response Rate (ORR)(15 months)
- Incidence and severity of AEs(36 months)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCCHepatocellular CarcinomaNCT01259193Fudan University50
已完成
2 期
Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of AgeAcute Myeloid Leukemia (AML)NCT00893373Technische Universität Dresden276
终止
2 期
Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast CancerBreast CancerNCT00525161Suleiman Massarweh11
已完成
1 期
Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaAdult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Recurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaNCT00131989National Cancer Institute (NCI)48
已完成
2 期
Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction CancerGastroesophageal Junction CancerEsophageal CancerNCT00917462Memorial Sloan Kettering Cancer Center35